Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results.
30 patients with acute exacerbations of multiple sclerosis were treated by ACTH, dexamethasone or methylprednisolone in a double-blind randomized study. Clinical parameters were assessed; cerebrospinal fluid and neurophysiological parameters (visual- and brainstem-evoked potentials) were evaluated at the beginning and at the end of treatment. Dexamethasone was more effective than ACTH and 6-methylprednisolone in shortening bout duration. Neither CSF nor neurophysiological parameters were significantly affected by therapy.
Milanese
C
C
Department of Neurology, Istituto Neurologico C. Besta, Milano, Italy.
La Mantia
L
L
Salmaggi
A
A
Campi
A
A
Eoli
M
M
Scaioli
V
V
Nespolo
A
A
Corridori
F
F
D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use*; D000328:Adult; D003907:Dexamethasone / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005072:Evoked Potentials, Auditory; D005074:Evoked Potentials, Visual; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D011897:Random Allocation
D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D008775:Methylprednisolone